

Special Issue

Cell Therapy in Ophthalmological Disease

Message from the Guest Editor

This Special Issue explores cutting-edge research and innovations aimed at regenerating ocular defects, assessing treatment efficacy through novel in vitro models, and introducing new cell therapies. Stem cell-based therapies show potential in repairing damaged retinal tissue and restoring visual function. Advances in gene editing techniques offer precise tools for correcting genetic mutations implicated in inherited eye disorders. In vitro models have evolved significantly, providing more accurate platforms to evaluate the efficacy and safety of cell therapies. Organoid cultures derived from patient-specific cells allow researchers to mimic complex ocular tissues, facilitating personalized treatment strategies. Novel cell therapies are emerging as promising treatments for a spectrum of ocular diseases. This Special Issue consolidates the latest research advancements, offering insights into the future landscape of ophthalmological cell therapy. By highlighting innovative approaches and transformative therapies, it seeks to catalyze further progress in the field, ultimately enhancing the quality of life for patients with ocular diseases.

Guest Editor

Prof. Dr. Florian K. Groeber-Becker

Laboratory for Experimental Ophthalmology, Department of Ophthalmology, University Clinic Düsseldorf, Merowingerplatz 1A, 40225 Düsseldorf, Germany

Deadline for manuscript submissions

closed (10 March 2025)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/217858

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.